Literature DB >> 7611728

Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease.

T Matilla1, A McCall, S H Subramony, H Y Zoghbi.   

Abstract

The autosomal dominant spinocerebellar ataxias are clinically and genetically a heterogeneous group of neurodegenerative disorders. Genetic studies have classified some of these disorders based on the mapping of their respective genes. The gene for Machado-Joseph disease, one type of spinocerebellar ataxia, has been mapped to the long arm of chromosome 14q24.3-ter. The gene for another spinocerebellar ataxia, which is clinically distinct from Machado-Joseph disease, has been also localized to the same region on 14q and has been named type 3 spinocerebellar ataxia. Recently, expansions of a CAG trinucleotide repeat in a novel gene on chromosome 14q32.1 were shown in 11 patients affected with Machado-Joseph disease. In this study, we analyzed the DNA samples from 103 individuals representing 42 independent families with dominantly inherited ataxia to determine whether any had the Machado-Joseph disease mutation. The Machado-Joseph disease CAG expansion was detected in 5 of these 42 families. Sixteen affected individuals displayed a normal allele containing 14 to 31 CAG repeats and an expanded allele ranging between 66 and 79 CAG repeats. Seven asymptomatic individuals showed an allele ranging between 67 and 80 CAG repeats. Two of these families had a phenotype consistent with Machado-Joseph disease while the other 3 had clinical features of type 3 spinocerebellar ataxia. These data suggest that a single locus at 14q32.1 is responsible for two forms of spinocerebellar ataxia, spinocerebellar ataxia type 3 and Machado-Joseph disease, and that this locus may account for approximately 11% of this group of dominantly inherited ataxias.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7611728     DOI: 10.1002/ana.410380113

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

Review 1.  The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias.

Authors:  S Di Donato
Journal:  Ital J Neurol Sci       Date:  1998-12

Review 2.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

3.  Different origins of mutations at the Machado-Joseph locus (MJD1)

Authors:  P Iughetti; M Zatz; M R Bueno; S K Marie
Journal:  J Med Genet       Date:  1996-05       Impact factor: 6.318

Review 4.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

Review 5.  The inherited ataxias and the new genetics.

Authors:  S R Hammans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

6.  A case of Machado-Joseph disease presenting with spastic paraparesis.

Authors:  A Kaneko; Y Narabayashi; K Itokawa; Y Nakazato; T Hosokawa; S Iwasaki; R Ohno; K Hamaguchi; M Ikeda; M Nomura
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-05       Impact factor: 10.154

Review 7.  The genetic defect causing Huntington's disease: repeated in other contexts?

Authors:  J F Gusella; F Persichetti; M E MacDonald
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 8.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

9.  Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation.

Authors:  L Schöls; G Amoiridis; J T Epplen; M Langkafel; H Przuntek; O Riess
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 10.  SCA3: neurological features, pathogenesis and animal models.

Authors:  Olaf Riess; Udo Rüb; Annalisa Pastore; Peter Bauer; Ludger Schöls
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.